SNM and the International Partnership for Critical Markers of Disease (CMOD) will jointly host a meeting on May 1 to examine U.S. Food and Drug Administration requirements for manufacturing PET radiopharmaceuticals.
The meeting is scheduled for the Natcher Auditorium at the National Institutes of Health (NIH) in Bethesda, MD, from 6:10 p.m. to 9:45 p.m.
SNM President-elect Dr. Michael Graham, Ph.D., director of nuclear medicine at the University of Iowa Carver College of Medicine in Iowa City, said the scientific community must work together to facilitate personalized medicine through the development of advanced imaging techniques and new radiopharmaceuticals that will enable physicians to more precisely locate disease and evaluate and monitor the effectiveness of therapy.
The SNM-CMOD event will take place after SNM's Multimodality Cardiovascular Molecular Imaging Symposium, set for April 30 to May 1, also at the NIH.
Related Reading
FDA clears SNM IND application, February 3, 2009
SNM criticizes NAS isotope report, January 16, 2009
SNM creates clinical trials network, October 7, 2008
SNM has 'serious concerns' over isotope situation, August 28, 2008
SNM draft report shows U.S. Mo-99 production years away, July 22, 2008
Copyright © 2009 AuntMinnie.com
